Tag Archives: Bristol Myers Squibb Co

Business, Finance, Occupation & Industry

Bristol-Myers Squibb Expansion to Add 350 Jobs

Leave a comment

By The Associated Press

Filed under: , , ,

Getty Images

NEW YORK — Drugmaker Bristol-Myers Squibb plans to spend about $250 million expanding a manufacturing complex it opened in 2009 for biologic treatments.

The New York company said Thursday that it will add two buildings to an 89-acre campus in Devens, Mass. One will be dedicated to the development of processes for the early production of biologic medicines. The second will house manufacturing for investigational drugs produced for clinical trials.

Biologic treatments are made from living cells instead of a chemical formula, and Bristol-Myers said they’re playing a growing role in its development of new therapies.

The expansion work will start later this year and be completed in 2015. Bristol-Myers Squibb Co. (BMY) expects to add 350 employees to the Devens location.

The complex opened in 2009 and has been used for large-scale bulk manufacturing of biologic treatments.

Permalink | Email this | Linking Blogs | Comments

From: http://www.dailyfinance.com/2013/04/12/bristol-myers-squibb-adds-jobs/

Business, Finance, Occupation & Industry

RBCC Targets Companion Diagnostics Opportunities in Booming $232 Billion Personalized Medicine Marke

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

RBCC Targets Companion Diagnostics Opportunities in Booming $232 Billion Personalized Medicine Market

NOKOMIS, Fla.–(BUSINESS WIRE)– As Rainbow Coral Corp.’s (OTCBB: RBCC) biotech subsidiary, Rainbow BioSciences, seeks out potentially lucrative new opportunities in the $232 billion personalized medicine market, the company announced today that it will target new innovations in the growing field of companion diagnostics.

The personalized medicine market in the U.S. is ripe for expansion, with PricewaterhouseCoopers predicting that the sector could grow to as much as $452 billion by 2015. One of the fastest-growing fields in the market is companion diagnostics, which could grow to as large as $42 billion by 2015, according to industry analysts TriMarkPublications.com.

The key to that growth will be innovation. Companion diagnostics is the use of genetic variation to chart different patient responses to specific drugs or biologic agents in order to create effective, efficient treatments tailored to a patient’s genetic profile. The emerging field is believed by many medical experts to have an increasingly important role to play in cancer treatments in coming years.

“Companion diagnostics represent the very cutting edge of technology in medicine today,” said RBCC CEO Patrick Brown. “We believe the key to our success is bringing desperately needed new innovations to the market that will improve patient outcomes and reduce healthcare costs. Companion diagnostics offer us the best opportunities to achieve that goal.”

For more information on Rainbow BioSciences’ personalized medicine initiatives, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Amgen Inc. (NAS: AMGN) .

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

RBCC: New Rainbow BioSciences Website Highlights Impressive Deal Flow

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

RBCC: New Rainbow BioSciences Website Highlights Impressive Deal Flow

NOKOMIS, Fla.–(BUSINESS WIRE)– Last week, Rainbow BioSciences, the biotechnology division of Rainbow Coral Corp. (OTCBB: RBCC), unveiled a new website highlighting its explorations into the multi-billion-dollar drug delivery and genome-mapping market.

To view the new website, please visit www.rainbowbiosciences.com.

In particular, the revamped site details the company’s new partnership with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before. Some experts believe that the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to $81.5 billion by 2015.

In addition, RBCC is close to partnering with a cutting-edge genome-mapping facility in Houston capable of helping doctors assess genetic variations in patients in order to create more effective, optimized drug treatment plans. The genetic testing sector is one of the fastest-growing segments of the global biotech industry, with some market experts expecting it to reach $2.2 billion by 2017.

“The partnerships that we’re targeting could help usher in a new era of healthcare: personalized medicine,” said RBCC CEO Patrick Brown. “We see big growth in store for this sector, and Rainbow BioSciences’ improved website will help us keep shareholders, potential investors and other interested parties up to date on our latest activities to bring these revolutionary technologies to a pharmacy or clinic near you.”

Rainbow BioSciences is dedicated to developing and marketing new medical and research technologies to compete in a fast-growing industry alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Valeant Pharmaceuticals International (NYS: VRX) .

For more information on these initiatives, please visit www.rainbowbiosciences.com/investors.html.

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

RBCC: TheraKine Joint Venture Offers Significant Opportunity in Licensing

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

RBCC: TheraKine Joint Venture Offers Significant Opportunity in Licensing

NOKOMIS, Fla.–(BUSINESS WIRE)– Only days after signing a joint venture agreement with cutting-edge drug delivery innovators TheraKine, Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC) is working hard to ensure that the partnership will be a fruitful one. Already, the company is searching for new targets that would benefit from adding licenses for the drug delivery protocols TheraKine and RBCC plan to roll out.

The global market for drug delivery technologies is driven by biologics and medications that can’t be administered effectively through traditional means. Some experts believe that the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to $81.5 billion by 2015.

In order to capture a piece of that growth, RBCC is seeking out healthcare providers for whom TheraKine’s advanced sustained-release delivery system could yield significant returns for their clients. TheraKine has developed and patented novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.

“Licensing this incredible new platform is going to be one of the key opportunities to making this a successful partnership,” said RBCC CEO Patrick Brown. “It’s a top priority for our company moving forward. The potential is limitless.”

Rainbow BioSciences develops and markets new medical and research technology innovations to compete in a fast-growing industry alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Valeant Pharmaceuticals International (NYS: VRX) .

RBCC is dedicated to delivering new medical research and technologies to a hungry global marketplace. For more information on RBCC‘s initiatives, please visit www.rainbowbiosciences.com/investors.html.

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

About TheraKine Ltd.

TheraKine Ltd. is …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

RBCC Forms Joint Venture With Cutting-Edge Drug Delivery Company TheraKine

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

RBCC Forms Joint Venture With Cutting-Edge Drug Delivery Company TheraKine

NOKOMIS, Fla.–(BUSINESS WIRE)– As part of a bold expansion into the $60 billion global drug delivery market, Rainbow BioSciences, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC), today announced it has formed a new partnership to solve the problems posed by systemic drug delivery.

RBCC signed a joint venture agreement with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before. The company has developed and patented these novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.

Additionally, this new sustained-release technology can also extend the patent life cycles of drugs, giving potential pharmaceutical partners a tremendous market advantage.

“TheraKine’s sustained-release delivery system could allow patients who now need daily injections to instead have one injection every four to six months,” said RBCC CEO Patrick Brown. “We expect the demand for this product to be very high once it’s made available, and RBCC plans to take a real stake in its success.”

Stan Yakatan, TheraKine’s CEO, said, “TheraKine is excited about the opportunity to partner with Rainbow to repurpose drugs with our sustained release technologies.”

RBCC is dedicated to delivering new medical research and technologies to a hungry global marketplace. For more information on RBCC‘s initiatives, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Amgen Inc. (NAS: AMGN) .

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

About TheraKine Ltd.

…read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

RBCC: Tech Innovations Drive Big Growth in $60 Billion Drug Delivery Market

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

RBCC: Tech Innovations Drive Big Growth in $60 Billion Drug Delivery Market

NOKOMIS, Fla.–(BUSINESS WIRE)– The next generation of advanced pharmaceutical technologies could be poised to fuel remarkable growth in the $60 billion global drug delivery market, and Rainbow Biosciences—the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC)—plans to be right in the middle of the action.

New drug delivery methods are seen by some pharmaceutical giants as a crucial growth generator, and new innovations are spreading across the healthcare sector. Many experts believe that personalized medicine is the future of healthcare, and customized drug delivery has the potential to drastically change the way value is assessed and compensated in the U.S. healthcare system.

RBCC is working hard to capitalize on the changing drug-delivery paradigm by partnering with key players in the field. The company is now in talks with an emerging company that owns technology with the potential to enable selective, site-specific delivery, allowing for lower drug concentrations and greatly reducing the risk of drug toxicity. In addition to helping millions of patients struggling with chronic conditions, this bold new technology can also extend the patent life cycles of drugs, giving potential pharmaceutical partners a tremendous market advantage.

For more information on Rainbow BioSciences’ current projects, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Amgen Inc. (NAS: AMGN) .

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

RBCC Nears Finalization of Partnership Agreement with Leading-Edge Pharmacogenomics Labs

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

RBCC Nears Finalization of Partnership Agreement with Leading-Edge Pharmacogenomics Labs

NOKOMIS, Fla.–(BUSINESS WIRE)– Rainbow Coral Corp. (OTCBB: RBCC), a biotech company focused on delivering new medical technologies and innovations, today reports its anticipation of partnering with a cutting-edge genome-mapping facility in Houston in the next few weeks.

The genetic testing sector is one of the fastest-growing segments of the global biotech industry, with some market experts expecting it to reach $2.2 billion by 2017. The cutting-edge science of pharmacogenomics is a field of study resulting from the Human Genome Project that seeks to help doctors assess genetic variations in patients in order to create more effective, optimized drug treatment plans.

RBCC sees it as the future of medicine.

“This is the next evolution in personalized medicine,” said RBCC CEO Patrick Brown. “Important differences in drug metabolism and response from person to person are often rooted in our genes. By studying a patient’s genotype, doctors can eliminate the trial-and-error approach to tailoring a safer, more efficient and more effective drug treatment plan.”

RBCC is turning its full attention to the exploration of new promising opportunities now that the company will no longer be partnering with Amarantus Biosciences, which has elected to pursue other opportunites. RBCC wishes Amarantus much success moving forward, and remains open to future partnering opportunities with the company.

In addition to its pharmacogenomics talks, RBCC is also currently working on a joint venture agreement with a privately held drug delivery company that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before.

For more information on Rainbow BioSciences’ current projects, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Amgen Inc. (NAS: AMGN) .

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Notable ETF Inflow Detected – VHT, BMY, ESRX, MDT

Leave a comment

By ETFChannel.com Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Health Care ETF (AMEX: VHT) where we have detected an approximate $53.0 million dollar inflow — that’s a 4.8% increase week over week in outstanding units (from 14,619,152 to 15,319,152). Among the largest underlying components of VHT, in trading today Bristol-Myers Squibb Co. (NYSE: BMY) is down about 0.1%, Express Scripts Holdings Co (NASD: ESRX) is down about 0.7%, and Medtronic, Inc. (NYSE: MDT) is up by about 0.4%. For a complete list of holdings, visit the VHT Holdings page »
Source: FULL ARTICLE at Forbes Markets

Business, Finance, Occupation & Industry

Notable ETF Outflow Detected – HDV, MO, MCD, BMY

Leave a comment

By ETFChannel.comLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares High Dividend Equity Fund (AMEX: HDV) where we have detected an approximate $94.0 million dollar outflow — that’s a 4.2% decrease week over week (from 37,950,000 to 36,350,000). Among the largest underlying components of HDV, in trading today Altria Group Inc (NYSE: MO) is off about 0.6%, McDonald’s Corp (NYSE: MCD) is down about 0.8%, and Bristol-Myers Squibb Co. (NYSE: BMY) is lower by about 0.2%. For a complete list of holdings, visit the HDV Holdings page »
Source: Forbes Markets